<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Res Treat</journal-id><journal-id journal-id-type="publisher-id">ART</journal-id><journal-title-group><journal-title>AIDS Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">2090-1240</issn><issn pub-type="epub">2090-1259</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24715982</article-id><article-id pub-id-type="pmc">3955667</article-id><article-id pub-id-type="doi">10.1155/2014/636584</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van Delft</surname><given-names>Yvon</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moecklinghoff</surname><given-names>Christiane</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Chelsea and Westminster Hospital, St. Stephens Centre, London SW10 9NH, UK</aff><aff id="I2"><sup>2</sup>Janssen Research and Development, High Wycombe HP12 4DP, UK</aff><aff id="I3"><sup>3</sup>Janssen EMEA, Tilburg, The Netherlands</aff><aff id="I4"><sup>4</sup>Janssen EMEA, Neuss, Germany</aff><author-notes><corresp id="cor1">*Mark Nelson: <email>mark.nelson@chelwest.nhs.uk</email></corresp><fn fn-type="other"><p>Academic Editor: Robert R. Redfield</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>636584</elocation-id><history><date date-type="received"><day>25</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Mark Nelson et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine or placebo, in combination with darunavir/ritonavir and optimized background treatment. In these trials, etravirine showed significantly higher rates of HIV RNA suppression when compared with placebo (61% versus 40% at Week 48). There was no significant rise of lipids or neuropsychiatric adverse events, but there was an increase in the risk of rash with etravirine treatment. In the SENSE trial, which evaluated etravirine and efavirenz in 157 treatment-na&#x000ef;ve patients in combination with 2 nucleoside analogues, there was a lower risk of lipid elevations and neuropsychiatric adverse events with etravirine when compared to efavirenz. Etravirine has been evaluated in three randomized switching studies. In the SSAT029 switch trial, 38 patients who had neuropsychiatric adverse events possibly related to efavirenz showed an improvement in these after switching to etravirine. The Swiss Switch-EE recruited 58 individuals without neuropsychiatric adverse events who were receiving efavirenz, and no benefit was shown when switching to etravirine. In the Spanish ETRA-SWITCH trial (<italic>n</italic> = 46), there were improvements in lipids when individuals switched from a protease inhibitor to etravirine. These switching trials were conducted in patients with full HIV RNA suppression: &#x0003c;50 copies/mL and with no history of virological failure or resistance to therapy. The results from these three randomized switching studies suggest a possible new role for etravirine, in combination with two nucleoside analogues, as a switching option for those with HIV RNA suppression but who are reporting adverse events possibly related to antiretroviral therapy. However a large well-powered trial would need to be conducted to strengthen the evidence from the pilot studies conducted so far.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>There are four nonnucleoside analogues recommended in Europe and North America for the treatment of HIV: efavirenz, etravirine, nevirapine, and rilpivirine [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Of these, efavirenz is the most widely recommended for first-line treatment, owing to the high rates of efficacy seen in large randomized trials [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. Nevirapine has shown levels of efficacy close to, but not equivalent with, efavirenz as a first-line treatment [<xref rid="B7" ref-type="bibr">7</xref>]. Nevirapine has recently been reformulated to a 400&#x02009;mg once daily extended release (XR) dosing, which has shown noninferior efficacy to the original dose of 200&#x02009;mg twice daily in treatment-na&#x000ef;ve patients [<xref rid="B8" ref-type="bibr">8</xref>]. Rilpivirine showed improved tolerability versus efavirenz in the ECHO and THRIVE studies, but higher rates of virological failure among those with baseline HIV RNA levels above 100,000&#x02009;copies/mL [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Efavirenz and rilpivirine have both been coformulated with tenofovir and emtricitabine into a single pill which is prescribed once daily: Atripla for efavirenz and Complera/Eviplera for rilpivirine [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Nevirapine XR has been developed as a single pill for once daily first-line use but is combined with two nucleoside analogues which are prescribed separately from the nevirapine [<xref rid="B8" ref-type="bibr">8</xref>]. Etravirine has only been approved for treatment of experienced patients [<xref rid="B12" ref-type="bibr">12</xref>]. Etravirine has not been coformulated with nucleoside analogues, and the daily approved dose involves two 200&#x02009;mg tablets [<xref rid="B13" ref-type="bibr">13</xref>]. Despite these possible drawbacks, etravirine may have a role as a switch option for patients who have HIV RNA suppression on other treatments but have developed adverse events.</p><p>There are several concerns over the safety profiles of efavirenz and nevirapine. Efavirenz causes a range of neuropsychiatric adverse events, in particular dizziness and mood and sleep disorders [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. These adverse events are generally mild and short term, but in some may be long-lasting. Efavirenz also causes rises in lipids [<xref rid="B16" ref-type="bibr">16</xref>] and there is a risk of rash [<xref rid="B17" ref-type="bibr">17</xref>]. Efavirenz showed teratogenicity in animal models, but the most recent guidance from the World Health Organization and the British HIV Association does permit continued use of efavirenz in pregnancy [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. This is because of evidence from a meta-analysis of outcomes in pregnant women treated with efavirenz showing no excess of birth abnormalities [<xref rid="B20" ref-type="bibr">20</xref>]. Nevirapine has been associated with severe skin reactions in a minority of patients, including Stevens-Johnsons syndrome, particularly if used in patients with high CD4 counts [<xref rid="B7" ref-type="bibr">7</xref>]; hepatotoxicity is an additional issue [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Patients with virological failure while taking first-line efavirenz, nevirapine, or rilpivirine have a significant risk of developing resistance to nonnucleosides and nucleoside analogues, which can restrict future treatment options [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. However etravirine has been shown to have antiviral activity against HIV with resistance to efavirenz or nevirapine [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>].</p><p>In this review, we discuss the potential role for etravirine as a switch option in those who develop adverse events while taking alternate antiretroviral treatments. Efficacy and safety results from the original DUET trials in highly experienced patients are discussed, together with the SENSE trial in first-line treatment. Three randomized studies evaluating the switch from efavirenz to etravirine have been conducted and are reviewed. The designs of these trials are shown in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec2"><title>2. The Development of Etravirine</title><p>The nonnucleoside etravirine has <italic>in vitro</italic> activity against both NNRTI-na&#x000ef;ve and resistant viruses [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. A proof-of-concept trial showed significant reductions in HIV RNA in treatment-na&#x000ef;ve individuals receiving etravirine as monotherapy for seven days [<xref rid="B26" ref-type="bibr">32</xref>]. A pilot study of etravirine was conducted (TMC125-C227) in NRTI and NNRTI experienced patients, comparing second-line treatment with optimized nucleoside analogues plus either etravirine or protease inhibitors [<xref rid="B27" ref-type="bibr">33</xref>]. This study was discontinued early, owing to a higher rate of virological failure in the etravirine arm. The results revealed that etravirine is needed to be used in combination with fully active antiretrovirals to ensure HIV RNA suppression.</p><p>Unlike other nonnucleoside analogues, etravirine was first evaluated in highly treatment-experienced patients. The results from the DUET 1 and 2 trials, where etravirine was evaluated in combination with darunavir/ritonavir, led to the regulatory approval for treatment-experienced patients at a 200&#x02009;mg twice daily dose [<xref rid="B28" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">27</xref>].</p><p>Although etravirine is approved at the 200&#x02009;mg twice daily dose, the long half-life of etravirine (30&#x02013;40 hours) supports once daily dosing [<xref rid="B30" ref-type="bibr">34</xref>]. Pharmacokinetic studies have evaluated the 400&#x02009;mg once daily dose of etravirine in treatment-na&#x000ef;ve patients [<xref rid="B31" ref-type="bibr">35</xref>] and those switching from efavirenz [<xref rid="B32" ref-type="bibr">36</xref>] and those switching from the 200&#x02009;mg twice daily dose of etravirine [<xref rid="B33" ref-type="bibr">37</xref>]. The results from these pharmacokinetic studies led to the once daily dose used in the SENSE trial and the switching studies described below.</p><p>After the completion of the DUET trials, extended pharmacovigilance demonstrated three cases of severe rash or hypersensitivity during etravirine treatment in routine clinical practice [<xref rid="B12" ref-type="bibr">12</xref>].</p></sec><sec id="sec3"><title>3. The DUET Trials</title><p>The DUET 1 and 2 trials recruited 1203 patients with preexisting resistance to nonnucleoside and protease inhibitors [<xref rid="B28" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">27</xref>]. The patients were randomized to either etravirine or placebo, which were prescribed with a background regimen (BR) of darunavir/ritonavir, nucleoside analogues, and optional enfuvirtide. This was a double-blind, placebo-controlled trial. Summary results from the DUET trials at Week 48 are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. Despite the high prevalence of NNRTI resistance at baseline, there was an efficacy advantage for the etravirine arm over placebo: 61% of patients having HIV RNA suppression below 50 copies/mL at Week 48 and 40% in the placebo arm. These efficacy benefits were maintained at Week 96 [<xref rid="B29" ref-type="bibr">27</xref>]. There was no increase in the risk of nervous system or psychiatric adverse events or in lipids in the etravirine arm when compared with placebo although there was a higher risk of Grades 1&#x02013;4 rash with etravirine (10% versus 4%). However the number of patients with serious rash (Grade 3 or 4) was 1.3% with etravirine and 0% with placebo; 2.2% of patients discontinued the etravirine arm due to rash and 0% with placebo. There was no significant increase in the risk of lipid abnormalities with etravirine when compared to placebo (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>Since the DUET trials were completed, etravirine has been combined with other novel antiretrovirals in triple combinations for use in highly treatment-experienced patients, such as darunavir/ritonavir and raltegravir [<xref rid="B34" ref-type="bibr">38</xref>, <xref rid="B35" ref-type="bibr">39</xref>].</p></sec><sec id="sec4"><title>4. The SENSE Trial</title><p>The double-blind, placebo-controlled SENSE trial [<xref rid="B36" ref-type="bibr">28</xref>] evaluated the efficacy and safety of etravirine and efavirenz in individuals na&#x000ef;ve to antiretroviral therapy. Patients with HIV RNA &#x0003e;5000&#x02009;copies/mL were randomised to etravirine 400&#x02009;mg once daily (<italic>n</italic> = 79) or efavirenz 600&#x02009;mg (<italic>n</italic> = 78), plus two nucleoside analogues. The primary objective of the trial was to compare the risk of neuropsychiatric adverse events after 12 weeks of treatment. However, efficacy was also evaluated, and patients were followed up on randomised treatment to Week 48. Summary results are shown in <xref ref-type="table" rid="tab3">Table 3</xref>.</p><p>In the Intent to Treat analysis at Week 48, 60/79 (76%) on etravirine and 58/78 (74%) on efavirenz had a HIV RNA &#x0003c;50&#x02009;copies/mL. In the on Treatment analysis, there were 92% with HIV RNA &#x0003c;50&#x02009;copies/mL for etravirine and 89% for efavirenz. Etravirine showed noninferior efficacy versus efavirenz in both analyses (<italic>P</italic> &#x0003c; 0.05) [<xref rid="B36" ref-type="bibr">28</xref>]. Four patients had virological failure in the etravirine arm; none developed resistance to nucleoside analogues or nonnucleosides. Seven demonstrated virological failure in the efavirenz arm; three developed treatment-emergent resistance to nucleoside analogues and/or nonnucleosides.</p><p>There were safety benefits to etravirine over efavirenz in this trial (<xref ref-type="table" rid="tab3">Table 3</xref>). The number of patients who developed Grades 2&#x02013;4 drug-related adverse events was smaller with etravirine. Fewer individuals discontinued from the etravirine arm for adverse events. The risk of nervous system or psychiatric adverse events was lower with etravirine. This difference persisted throughout the trial; at Week 48 visit, the percentage with ongoing neuropsychiatric adverse events was 6.3% for etravirine and 21.5% for efavirenz [<xref rid="B36" ref-type="bibr">28</xref>]. Fewer patients developed elevations in lipids in the etravirine arm. However the risk of developing skin or subcutaneous disorders was similar with the two drugs.</p><p>The SENSE trial was not designed to demonstrate differences in efficacy for etravirine when compared with efavirenz in first-line treatment, and etravirine is still only approved for use in treatment-experienced patients. However the results from the trial do highlight the differences in safety and tolerability between etravirine and efavirenz.</p></sec><sec id="sec5"><title>5. The UK SSAT029 Trial</title><p>Results from an open-label pilot study suggested that patients with undetectable HIV RNA could be successfully switched to etravirine [<xref rid="B37" ref-type="bibr">40</xref>]. Consequently, a double-blind, placebo-controlled cross over trial was designed to evaluate whether a switch from efavirenz to etravirine could lead to improvements in nervous system and psychiatric side effects [<xref rid="B38" ref-type="bibr">29</xref>]. The trial recruited 38 patients who were receiving efavirenz with two nucleoside analogues and who had HIV RNA suppression &#x0003c;50&#x02009;copies/mL, but ongoing CNS symptoms possibly related to efavirenz. In the immediate switch arm, patients changed from efavirenz to etravirine 400&#x02009;mg once daily for 24 weeks, while continuing their nucleoside analogues. In the delayed switch arm, patients maintained their pretrial treatment for 12 weeks, and then switched to etravirine at Week 12, continuing to Week 24. Patients were evaluated for adverse events after 12 weeks and 24 weeks of treatment.</p><p>At Week 12 visit there was a significant reduction in CNS adverse events in the patients in the immediate switch arm, whereas there was no change in CNS symptoms in the patients continuing efavirenz (<xref ref-type="table" rid="tab4">Table 4</xref>). The patients in the delayed arm who then switched to etravirine at Week 12 showed improvements in their CNS adverse events by Week 24. <xref ref-type="table" rid="tab4">Table 4</xref> shows the overall improvements in CNS adverse events after switching to etravirine, combining both treatment arms. Switching from efavirenz to etravirine led to statistically significant improvements in overall adverse events, insomnia, abnormal dreams, and nervousness (<italic>P</italic> &#x0003c; 0.05 for each comparison). In addition there were statistically significant reductions in total cholesterol after the switch from efavirenz to etravirine. In the analysis of clinical adverse events, there was no difference between the arms for depression (<xref ref-type="table" rid="tab4">Table 4</xref>). All patients maintained HIV RNA levels below 50&#x02009;copies/mL at all study visits.</p></sec><sec id="sec6"><title>6. Swiss SWITCH-EE Trial</title><p>This was a double-blind, placebo-controlled cross over trial, evaluating 58 individuals who had no side effects and had tolerated efavirenz for at least three months with HIV RNA suppression below 50&#x02009;copies/mL [<xref rid="B39" ref-type="bibr">30</xref>]. In a cross over design, the patients received either etravirine 400&#x02009;mg once daily or efavirenz 600&#x02009;mg once daily plus 2 NRTIs for six weeks, and then switched to the alternate NNRTI for a further six weeks. The primary endpoint was patient preference for the first or second NNRTI received and was assessed after the full 12 weeks of the trial.</p><p>At the end of the trial, there was no significant difference in preference for either NNRTI. However there was an association between patient preference and the order in which patients received the NNRTIs: patients who continued efavirenz during the first phase of the trial preferred efavirenz (15/21 = 71%), whereas those who commenced with etravirine in the first phase preferred etravirine (16/17 = 94%). Quality of sleep, depression, anxiety, and stress scores did not differ significantly between the two groups. The median lipid levels improved during the etravirine phase of the trial (<xref ref-type="table" rid="tab5">Table 5</xref>).</p><p>The main safety results from this trial differ from the UK SSAT029 trial, described above. In the Swiss SWITCH-EE trial, patients did not have possible efavirenz related neuropsychiatric adverse events at baseline, whereas this was an entry requirement for the UK SSAT029 study. In addition, the authors of the Swiss SWITCH-EE study suggested that the order effect of preference in this trial could be related to the reemergence of neuropsychiatric adverse events in the group who switched to etravirine during the first phase and then restarted efavirenz in the second phase. By contrast, the patients who continued efavirenz for the first six weeks, and then switched to etravirine later, would not have experienced reemergence of these neuropsychiatric adverse events. All patients maintained HIV RNA levels below 50&#x02009;copies/mL during the 12-week trial.</p></sec><sec id="sec7"><title>7. Spanish ETRA-Switch Trial</title><p>This 48-week trial recruited 46 patients with HIV RNA suppression &#x0003c;50&#x02009;copies/mL while receiving PI-based treatment [<xref rid="B40" ref-type="bibr">31</xref>]. Patients recruited had a history of either dyslipidemia, gastrointestinal disturbancem or low satisfaction with their current antiretroviral regimen. Patients with a history of NRTI or NNRTI resistance were excluded from the trial. The patients were randomized to either continue their protease inhibitor or switch to etravirine 400&#x02009;mg once daily for 48 weeks.</p><p>The 24-week results from this study have been presented. All patients maintained HIV RNA levels below 50&#x02009;copies/mL to Week 24. There were statistically significant reductions in total cholesterol, HDL cholesterol, and triglycerides in the etravirine arm (<xref ref-type="table" rid="tab5">Table 5</xref>) with no significant change in the protease inhibitor arm. One patient in each arm discontinued from the trial for adverse events (gastrointestinal disturbance in the etravirine arm and hypercholesterolemia in the protease inhibitor arm). In a pharmacokinetic substudy, those in the etravirine arm maintained etravirine trough concentrations above 4&#x02009;ng/mL throughout the trial.</p></sec><sec id="sec8"><title>8. Etravirine in Novel Combinations</title><p>In addition to the switch studies described above, etravirine has been evaluated in pilot studies in combination with other new antiretrovirals [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>]. For patients who already have resistance to nucleoside analogues, nonnucleosides, and protease inhibitors, the combination of etravirine with the integrase inhibitor raltegravir, the CCR5 antagonist maraviroc, or the protease inhibitor darunavir/ritonavir could provide a high enough genetic barrier to overcome high levels of preexisting drug resistance.</p></sec><sec id="sec9"><title>9. Conclusions</title><p>The combined results from the randomised trials of etravirine suggest a role as a switch option for patients who have adverse events while receiving other antiretroviral treatments. Patients who have ongoing neuropsychiatric adverse events while receiving efavirenz show improvements after switching to etravirine based on the UK SSAT029 study [<xref rid="B38" ref-type="bibr">29</xref>]. However in the Swiss SWITCH-EE study, where individuals did not report neuropsychiatric adverse events at screening, there was no significant benefit from the switch to etravirine [<xref rid="B39" ref-type="bibr">30</xref>]. The results from the Spanish ETRA-SWITCH trial show improvements in lipids after switching from a protease inhibitor to etravirine [<xref rid="B40" ref-type="bibr">31</xref>]. There were also improvements in lipids with etravirine when compared to efavirenz in the SENSE, Swiss SWITCH-EE, and UK SSAT029 trials. The clinical significance of these changes in lipids is unclear.</p><p>The clinical trials evaluating these switches were not statistically powered to demonstrate equivalent rates of HIV RNA suppression for etravirine when compared with the control arm [<xref rid="B44" ref-type="bibr">44</xref>]. Patients should be carefully selected on the basis of the inclusion criteria for the trials, including HIV RNA suppression &#x0003c;50&#x02009;copies/mL and no evidence for NRTI/NNRTI resistance during prior virological failure. A new randomised clinical trial, powered for noninferiority would be required to validate the results from the pilot studies conducted so far. This trial would need to show that a switch to etravirine maintained HIV RNA suppression in people previously suppressed on other treatments and also provided a safety benefit.</p></sec></body><back><sec sec-type="conflict"><title>Conflict of Interests</title><p>Dr. Mark Nelson has received consultancy payments from Janssen for presentations and advisory boards. Yvon van Delft and Dr. Christiane Moecklighoff are employees of Janssen, which developed the drug etravirine. Dr. Andrew Hill works as a consultant for Janssen.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="other"><collab>DHHS guidelines</collab><article-title>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents</article-title><comment>Department of Health and Human Services, 2012, <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/37/whats-new-in-the-guidelines">http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/37/whats-new-in-the-guidelines</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Aberg</surname><given-names>J</given-names></name><name><surname>Hoy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2012</year><volume>308</volume><issue>4</issue><fpage>387</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">22820792</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><collab>European treatment guidelines</collab><comment><ext-link ext-link-type="uri" xlink:href="http://eacsociety.org/guidelines">http://eacsociety.org/guidelines</ext-link></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddler</surname><given-names>SA</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><name><surname>DiRienzo</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Class-sparing regimens for initial treatment of HIV-1 infection</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>358</volume><issue>20</issue><fpage>2095</fpage><lpage>2106</lpage><pub-id pub-id-type="other">2-s2.0-43549094732</pub-id><pub-id pub-id-type="pmid">18480202</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennox</surname><given-names>JL</given-names></name><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>DS</given-names></name></person-group><article-title>Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2010</year><volume>55</volume><issue>1</issue><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">20404738</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daar</surname><given-names>ES</given-names></name><name><surname>Tierney</surname><given-names>C</given-names></name><name><surname>Fischl</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2011</year><volume>154</volume><issue>7</issue><fpage>445</fpage><lpage>456</lpage><pub-id pub-id-type="other">2-s2.0-80052922849</pub-id><pub-id pub-id-type="pmid">21320923</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leth</surname><given-names>F</given-names></name><name><surname>Phanuphak</surname><given-names>P</given-names></name><name><surname>Ruxrungtham</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study</article-title><source><italic>The Lancet</italic></source><year>2004</year><volume>363</volume><issue>9417</issue><fpage>1253</fpage><lpage>1263</lpage><pub-id pub-id-type="other">2-s2.0-11144357656</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gathe</surname><given-names>J</given-names></name><name><surname>Andrade-Villanueva</surname><given-names>J</given-names></name><name><surname>Santiago</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-na&#x000ef;ve HIV-1-infected patients</article-title><source><italic>Antiviral Therapy</italic></source><year>2011</year><volume>16</volume><issue>5</issue><fpage>759</fpage><lpage>769</lpage><pub-id pub-id-type="other">2-s2.0-80052465229</pub-id><pub-id pub-id-type="pmid">21817198</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Cahn</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-na&#x000ef;ve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2012</year><volume>60</volume><issue>1</issue><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="other">2-s2.0-84856854214</pub-id><pub-id pub-id-type="pmid">22343174</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="other"><collab>European Medicines Agency (EMA)</collab><article-title>Efavirenz summary of product characteristics</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf</ext-link></comment></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="other"><collab>European Medicines Agency (EMA)</collab><article-title>Rilpivirine (Edurant) summary of product characteristics</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf</ext-link></comment></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="other"><collab>European Medicines Agency (EMA)</collab><article-title>Etravirine summary of product characteristics</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf</ext-link></comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Kakuda</surname><given-names>T</given-names></name><name><surname>de Smedt</surname><given-names>G</given-names></name><name><surname>Leemans</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bioavailability of etravirine 200&#x02009;mg administered as a single 200&#x02009;mg tablet versus two 100&#x02009;mg tablets in HIV-negative, healthy volunteers</article-title><conf-name>Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention</conf-name><conf-date>July 2011</conf-date><conf-loc>Rome, Italy</conf-loc></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Moreno</surname><given-names>JA</given-names></name><name><surname>Fumaz</surname><given-names>CR</given-names></name><name><surname>Ferrer</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management: a neurobehavioral review</article-title><source><italic>AIDS Reviews</italic></source><year>2009</year><volume>11</volume><issue>2</issue><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="other">2-s2.0-68049115405</pub-id><pub-id pub-id-type="pmid">19529750</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzard</surname><given-names>B</given-names></name><name><surname>Balkin</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name></person-group><article-title>Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review</article-title><source><italic>AIDS Reviews</italic></source><year>2010</year><volume>12</volume><issue>2</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="other">2-s2.0-77956667215</pub-id><pub-id pub-id-type="pmid">20571601</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Sawyer</surname><given-names>W</given-names></name><name><surname>Gazzard</surname><given-names>B</given-names></name></person-group><article-title>Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels</article-title><source><italic>HIV Clinical Trials</italic></source><year>2009</year><volume>10</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="other">2-s2.0-64949092835</pub-id><pub-id pub-id-type="pmid">19362991</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="other"><collab>US Food and Drug Administration</collab><article-title>Efavirenz prescribing information</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020972s035,021360s023lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020972s035,021360s023lbl.pdf</ext-link></comment></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="other"><collab>World Health Organisation</collab><article-title>Technical update on treatment optimisation. Use of efavirenz during pregnancy. A public health perspective</article-title><comment>2012, <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/70920/1/9789241503792_eng.pdf">http://apps.who.int/iris/bitstream/10665/70920/1/9789241503792_eng.pdf
</ext-link></comment></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="other"><collab>BHIVA guidelines</collab><comment>2012, <ext-link ext-link-type="uri" xlink:href="http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv1029_2.pdf">http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv1029_2.pdf</ext-link></comment></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>N</given-names></name><name><surname>Calmy</surname><given-names>A</given-names></name><name><surname>Mofenson</surname><given-names>L</given-names></name></person-group><article-title>Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis</article-title><source><italic>AIDS</italic></source><year>2011</year><volume>25</volume><issue>18</issue><fpage>2301</fpage><lpage>2304</lpage><pub-id pub-id-type="other">2-s2.0-80855123632</pub-id><pub-id pub-id-type="pmid">21918421</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Blanco</surname><given-names>JL</given-names></name><name><surname>Arnaiz</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy</article-title><source><italic>AIDS</italic></source><year>2001</year><volume>15</volume><issue>10</issue><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="other">2-s2.0-0035816360</pub-id><pub-id pub-id-type="pmid">11426070</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Sawyer</surname><given-names>AW</given-names></name><name><surname>Pillay</surname><given-names>D</given-names></name></person-group><article-title>Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2008</year><volume>47</volume><issue>5</issue><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="other">2-s2.0-49449099010</pub-id><pub-id pub-id-type="pmid">18662137</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><collab>The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group</collab><article-title>Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice</article-title><source><italic>AIDS</italic></source><year>2005</year><volume>19</volume><issue>5</issue><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="other">2-s2.0-17144369901</pub-id><pub-id pub-id-type="pmid">15764854</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>AD</given-names><suffix>Jr.</suffix></name><name><surname>Lewi</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2004</year><volume>47</volume><issue>10</issue><fpage>2550</fpage><lpage>2560</lpage><pub-id pub-id-type="other">2-s2.0-2342620790</pub-id><pub-id pub-id-type="pmid">15115397</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andries</surname><given-names>K</given-names></name><name><surname>Azijn</surname><given-names>H</given-names></name><name><surname>Thielemans</surname><given-names>T</given-names></name><etal/></person-group><article-title>TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2004</year><volume>48</volume><issue>12</issue><fpage>4680</fpage><lpage>4686</lpage><pub-id pub-id-type="other">2-s2.0-9644291579</pub-id><pub-id pub-id-type="pmid">15561844</pub-id></element-citation></ref><ref id="B28"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katlama</surname><given-names>C</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><name><surname>Lalezari</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials</article-title><source><italic>AIDS</italic></source><year>2009</year><volume>23</volume><issue>17</issue><fpage>2289</fpage><lpage>2300</lpage><pub-id pub-id-type="other">2-s2.0-70449368908</pub-id><pub-id pub-id-type="pmid">19710593</pub-id></element-citation></ref><ref id="B29"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katlama</surname><given-names>C</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Mills</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials</article-title><source><italic>Antiviral Therapy</italic></source><year>2010</year><volume>15</volume><issue>7</issue><fpage>1045</fpage><lpage>1052</lpage><pub-id pub-id-type="other">2-s2.0-78649971571</pub-id><pub-id pub-id-type="pmid">21041921</pub-id></element-citation></ref><ref id="B36"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzard</surname><given-names>B</given-names></name><name><surname>Duvivier</surname><given-names>C</given-names></name><name><surname>Zagler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results</article-title><source><italic>AIDS</italic></source><year>2011</year><volume>25</volume><issue>18</issue><fpage>2249</fpage><lpage>2258</lpage><pub-id pub-id-type="other">2-s2.0-80855130709</pub-id><pub-id pub-id-type="pmid">21881478</pub-id></element-citation></ref><ref id="B38"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Winston</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine</article-title><source><italic>AIDS</italic></source><year>2011</year><volume>25</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="other">2-s2.0-78650308773</pub-id><pub-id pub-id-type="pmid">21099666</pub-id></element-citation></ref><ref id="B39"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Calmy</surname><given-names>A</given-names></name><name><surname>Delhumeau</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomized crossover study to compare efavirenz and etravirine treatment</article-title><source><italic>AIDS</italic></source><year>2011</year><volume>25</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21076278</pub-id></element-citation></ref><ref id="B40"><label>31</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Echeverria</surname><given-names>P</given-names></name><name><surname>Bonjoch</surname><given-names>A</given-names></name><name><surname>Puig</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pilot study to assess the efficacy and safety of switching protease inhibitor to once-daily etravirine in HIV-infected subjects with viral suppression (ETRA-SWITCH STUDY)</article-title><conf-name>Proceedings of the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC '11)</conf-name><conf-date>September 2011</conf-date><publisher-loc>Chicago, Ill, USA</publisher-loc></element-citation></ref><ref id="B26"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruzdev</surname><given-names>B</given-names></name><name><surname>Rakhmanova</surname><given-names>A</given-names></name><name><surname>Doubovskaya</surname><given-names>E</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral na&#x000ef;ve, HIV-1 infected subjects</article-title><source><italic>AIDS</italic></source><year>2003</year><volume>17</volume><issue>17</issue><fpage>2487</fpage><lpage>2494</lpage><pub-id pub-id-type="other">2-s2.0-12144289848</pub-id><pub-id pub-id-type="pmid">14600520</pub-id></element-citation></ref><ref id="B27"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruxrungtham</surname><given-names>K</given-names></name><name><surname>Pedro</surname><given-names>RJ</given-names></name><name><surname>Latiff</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-na&#x000ef;ve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227</article-title><source><italic>HIV Medicine</italic></source><year>2008</year><volume>9</volume><issue>10</issue><fpage>883</fpage><lpage>896</lpage><pub-id pub-id-type="other">2-s2.0-55749085253</pub-id><pub-id pub-id-type="pmid">18795960</pub-id></element-citation></ref><ref id="B30"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;ller-Gy&#x000fc;re</surname><given-names>M</given-names></name><name><surname>Kakuda</surname><given-names>TN</given-names></name><name><surname>Raoof</surname><given-names>A</given-names></name><name><surname>de Smedt</surname><given-names>G</given-names></name><name><surname>Hoetelmans</surname><given-names>RMW</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics of etravirine</article-title><source><italic>Clinical Pharmacokinetics</italic></source><year>2009</year><volume>48</volume><issue>9</issue><fpage>561</fpage><lpage>574</lpage><pub-id pub-id-type="other">2-s2.0-69849107159</pub-id><pub-id pub-id-type="pmid">19725591</pub-id></element-citation></ref><ref id="B31"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Lalezari</surname><given-names>JP</given-names></name><name><surname>Osiyemi</surname><given-names>OO</given-names></name><etal/></person-group><article-title>Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults</article-title><source><italic>Antiviral Therapy</italic></source><year>2010</year><volume>15</volume><issue>5</issue><fpage>711</fpage><lpage>720</lpage><pub-id pub-id-type="other">2-s2.0-77957328851</pub-id><pub-id pub-id-type="pmid">20710052</pub-id></element-citation></ref><ref id="B32"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boffito</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Lamorde</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2009</year><volume>52</volume><issue>2</issue><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="other">2-s2.0-70349690552</pub-id><pub-id pub-id-type="pmid">19620877</pub-id></element-citation></ref><ref id="B33"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Ktorza</surname><given-names>N</given-names></name><name><surname>Fourati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study</article-title><source><italic>HIV Clinical Trials</italic></source><year>2012</year><volume>13</volume><issue>5</issue><fpage>284</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">23134629</pub-id></element-citation></ref><ref id="B34"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazdanpanah</surname><given-names>Y</given-names></name><name><surname>Fagard</surname><given-names>C</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><etal/></person-group><article-title>High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2009</year><volume>49</volume><issue>9</issue><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="other">2-s2.0-72849119170</pub-id><pub-id pub-id-type="pmid">19814627</pub-id></element-citation></ref><ref id="B35"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imaz</surname><given-names>A</given-names></name><name><surname>del Saz</surname><given-names>SV</given-names></name><name><surname>Ribas</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2009</year><volume>52</volume><issue>3</issue><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="other">2-s2.0-71049149300</pub-id><pub-id pub-id-type="pmid">19654552</pub-id></element-citation></ref><ref id="B37"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Khatib</surname><given-names>N</given-names></name><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Gazzard</surname><given-names>BG</given-names></name><name><surname>Nelson</surname><given-names>M</given-names></name></person-group><article-title>Etravirine use in clinical practice: 48-week data from a single-centre cohort</article-title><source><italic>Journal of the International AIDS Society</italic></source><year>2008</year><volume>11</volume><issue>supplement 1, article P49</issue></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>P</given-names></name><name><surname>Perez</surname><given-names>I</given-names></name><name><surname>Laguno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study</article-title><source><italic>Journal of Antimicrobial Chemotherapy</italic></source><year>2014</year><volume>69</volume><issue>3</issue><fpage>742</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">24128667</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>R</given-names></name><name><surname>Paris</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy</article-title><source><italic>Antiviral Therapy</italic></source><year>2012</year><volume>17</volume><issue>8</issue><fpage>1601</fpage><lpage>1604</lpage><pub-id pub-id-type="pmid">22941896</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozza</surname><given-names>S</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>Visco</surname><given-names>F</given-names></name><etal/></person-group><article-title>Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience</article-title><source><italic>AIDS</italic></source><year>2010</year><volume>24</volume><issue>6</issue><fpage>924</fpage><lpage>928</lpage><pub-id pub-id-type="other">2-s2.0-77949551533</pub-id><pub-id pub-id-type="pmid">20154578</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Sabin</surname><given-names>C</given-names></name></person-group><article-title>Designing and interpreting HIV noninferiority trials in na&#x000ef;ve and experienced patients</article-title><source><italic>AIDS</italic></source><year>2008</year><volume>22</volume><issue>8</issue><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="other">2-s2.0-43649090700</pub-id><pub-id pub-id-type="pmid">18453850</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Design of the six main randomized trials of etravirine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Trial [ref]</th><th align="center" rowspan="1" colspan="1">Treatment arms (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Inclusion</th><th align="center" rowspan="1" colspan="1">Duration</th><th align="center" rowspan="1" colspan="1">Primary endpoint</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">DUET [<xref rid="B28" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">27</xref>]</td><td align="center" rowspan="1" colspan="1">BR + ETR (<italic>n</italic> = 599)</td><td align="center" rowspan="2" colspan="1">Experienced</td><td align="center" rowspan="2" colspan="1">96 weeks</td><td align="center" rowspan="2" colspan="1">HIV RNA &#x0003c;50&#x02009;c/mL</td></tr><tr><td align="center" rowspan="1" colspan="1">BR + placebo (<italic>n</italic> = 604)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">
SENSE [<xref rid="B36" ref-type="bibr">28</xref>]</td><td align="center" rowspan="1" colspan="1">2NRTI + ETR (<italic>n</italic> = 77)</td><td align="center" rowspan="2" colspan="1">Na&#x000ef;ve</td><td align="center" rowspan="2" colspan="1">48 weeks</td><td align="center" rowspan="2" colspan="1">CNS adverse events</td></tr><tr><td align="center" rowspan="1" colspan="1">2NRTI + EFV (<italic>n</italic> = 79)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">
UK SSAT029 [<xref rid="B38" ref-type="bibr">29</xref>]</td><td align="center" rowspan="1" colspan="1">2NRTI + ETR (<italic>n</italic> = 20)</td><td align="center" rowspan="2" colspan="1">HIV RNA &#x0003c;50</td><td align="center" rowspan="2" colspan="1">24 weeks</td><td align="center" rowspan="2" colspan="1">CNS adverse events</td></tr><tr><td align="center" rowspan="1" colspan="1">2NRTI + EFV (<italic>n</italic> = 18)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">
Swiss SWITCH-EE [<xref rid="B39" ref-type="bibr">30</xref>]</td><td align="center" rowspan="1" colspan="1">2NRTI + ETR (<italic>n</italic> = 28)</td><td align="center" rowspan="2" colspan="1">HIV RNA &#x0003c;50</td><td align="center" rowspan="2" colspan="1">12 weeks</td><td align="center" rowspan="2" colspan="1">Patient satisfaction</td></tr><tr><td align="center" rowspan="1" colspan="1">2NRTI + EFV (<italic>n</italic> = 30)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">
ETRA-SWITCH [<xref rid="B40" ref-type="bibr">31</xref>]</td><td align="center" rowspan="1" colspan="1">2NRTI + ETR (<italic>n</italic> = 24)</td><td align="center" rowspan="2" colspan="1">HIV RNA &#x0003c;50</td><td align="center" rowspan="2" colspan="1">48 weeks</td><td align="center" rowspan="2" colspan="1">HIV RNA &#x0003c;50&#x02009;c/mL</td></tr><tr><td align="center" rowspan="1" colspan="1">2NRTI + PI/r (<italic>n</italic> = 22)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>DUET trials: summary efficacy and safety results by treatment arm, to Week 48.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Etravirine + BR (<italic>n</italic> = 599)</th><th align="center" rowspan="1" colspan="1">Placebo + BR (<italic>n</italic> = 604)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HIV RNA &#x0003c;50&#x02009;c/mL, ITT</td><td align="center" rowspan="1" colspan="1">363 (61%)</td><td align="center" rowspan="1" colspan="1">240 (40%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Any grade 3 or 4 adverse event</td><td align="center" rowspan="1" colspan="1">199 (33%)</td><td align="center" rowspan="1" colspan="1">211 (35%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events leading to discontinuation</td><td align="center" rowspan="1" colspan="1">43 (7%)</td><td align="center" rowspan="1" colspan="1">34 (6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Grades 1&#x02013;4 clinical adverse events of interest</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nervous system</td><td align="center" rowspan="1" colspan="1">103 (17%)</td><td align="center" rowspan="1" colspan="1">119 (20%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Psychiatric</td><td align="center" rowspan="1" colspan="1">100 (17%)</td><td align="center" rowspan="1" colspan="1">118 (20%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rash</td><td align="center" rowspan="1" colspan="1">60 (10%)</td><td align="center" rowspan="1" colspan="1">21 (4%)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Grades 3-4 laboratory abnormalities</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated ALT</td><td align="center" rowspan="1" colspan="1">22 (4%)</td><td align="center" rowspan="1" colspan="1">12 (2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated AST</td><td align="center" rowspan="1" colspan="1">19 (3%)</td><td align="center" rowspan="1" colspan="1">12 (2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated total cholesterol</td><td align="center" rowspan="1" colspan="1">48 (8%)</td><td align="center" rowspan="1" colspan="1">32 (5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated LDL</td><td align="center" rowspan="1" colspan="1">42 (7%)</td><td align="center" rowspan="1" colspan="1">39 (7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated triglycerides</td><td align="center" rowspan="1" colspan="1">55 (10%)</td><td align="center" rowspan="1" colspan="1">35 (6%)</td></tr></tbody></table><table-wrap-foot><fn><p>BR: background regimen of optimized nucleoside analogues plus optional enfuvirtide.</p></fn><fn><p>*<italic>P</italic> &#x0003c; 0.05, comparison between treatment arms at Week 48.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>SENSE trial: summary efficacy and safety results by treatment arm, to Week 48.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Etravirine arm (<italic>n</italic> = 79)</th><th align="center" rowspan="1" colspan="1">Efavirenz arm (<italic>n</italic> = 78)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HIV RNA &#x0003c;50&#x02009;c/mL, ITT</td><td align="center" rowspan="1" colspan="1">60 (76%)</td><td align="center" rowspan="1" colspan="1">58 (74%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Any Grades 2&#x02013;4 drug-related adverse event</td><td align="center" rowspan="1" colspan="1">21 (27%)</td><td align="center" rowspan="1" colspan="1">33 (42%)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events leading to discontinuation</td><td align="center" rowspan="1" colspan="1">6 (8%)</td><td align="center" rowspan="1" colspan="1">13 (17%)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Grades 2&#x02013;4 drug-related clinical adverse <break/>events of interest</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nervous system</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">13 (17%)*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Psychiatric</td><td align="center" rowspan="1" colspan="1">4 (5%)</td><td align="center" rowspan="1" colspan="1">12 (15%)*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Skin or subcutaneous disorders</td><td align="center" rowspan="1" colspan="1">9 (11.4%)</td><td align="center" rowspan="1" colspan="1">9 (11.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Grades 3-4 laboratory abnormalities</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypophosphatemia</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Neutropenia</td><td align="center" rowspan="1" colspan="1">6 (8%)</td><td align="center" rowspan="1" colspan="1">3 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated ALT</td><td align="center" rowspan="1" colspan="1">2 (3%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated AST</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">2 (3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated total cholesterol</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">6 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated LDL</td><td align="center" rowspan="1" colspan="1">2 (3%)</td><td align="center" rowspan="1" colspan="1">8 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Elevated triglycerides</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (3%)</td></tr></tbody></table><table-wrap-foot><fn><p>*<italic>P</italic> &#x0003c; 0.05, comparison between treatment arms at Week 48.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>UK SSAT029 trial: changes in CNS adverse events by treatment arm, to Week 12.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Etravirine*(<italic>n</italic> = 20)</th><th align="center" rowspan="1" colspan="1">Efavirenz*(<italic>n</italic> = 18)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Grades 2&#x02013;4 CNS adverse events</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;All Grades 2&#x02013;4 CNS adverse events</td><td align="center" rowspan="1" colspan="1">60%</td><td align="center" rowspan="1" colspan="1">81%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median number of CNS adverse events</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dizziness</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">19%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Depression</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">19%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Insomnia</td><td align="center" rowspan="1" colspan="1">37%</td><td align="center" rowspan="1" colspan="1">60%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Anxiety</td><td align="center" rowspan="1" colspan="1">25%</td><td align="center" rowspan="1" colspan="1">44%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Impaired concentration</td><td align="center" rowspan="1" colspan="1">30%</td><td align="center" rowspan="1" colspan="1">31%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Headache</td><td align="center" rowspan="1" colspan="1">5%</td><td align="center" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Somnolence</td><td align="center" rowspan="1" colspan="1">30%</td><td align="center" rowspan="1" colspan="1">31%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Fatigue</td><td align="center" rowspan="1" colspan="1">35%</td><td align="center" rowspan="1" colspan="1">44%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Abnormal dreams</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">63%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nervousness</td><td align="center" rowspan="1" colspan="1">9%</td><td align="center" rowspan="1" colspan="1">29%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hallucinations</td><td align="center" rowspan="1" colspan="1">0%</td><td align="center" rowspan="1" colspan="1">7%</td></tr></tbody></table><table-wrap-foot><fn><p>*Patients in the delayed (efavirenz) arm switched to etravirine at Week 12; patients in the immediate etravirine arm remained on etravirine after Week 12.</p></fn></table-wrap-foot></table-wrap><table-wrap-group id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Changes in metabolic parameters in the Swiss SWITCH-EE trial and the Spanish ETRA-SWITCH trial.</p></caption><table-wrap id="tab5a" orientation="portrait" position="anchor"><caption><p>(a) Swiss SWITCH-EE trial: changes in lipids six weeks after switching from efavirenz to etravirine treatment (mmol/L)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Lab parameter&#x02009;<break/>Median (IQ range)</th><th align="center" rowspan="1" colspan="1">End of efavirenz phase</th><th align="center" rowspan="1" colspan="1">End of etravirine phase</th><th align="center" rowspan="1" colspan="1">Change between EFV and ETR phases (<italic>n</italic> = 55)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ALT</td><td align="center" rowspan="1" colspan="1">33.0 (24&#x02013;55.5)</td><td align="center" rowspan="1" colspan="1">37.0 (26&#x02013;64)</td><td align="center" rowspan="1" colspan="1">0.0 (&#x02212;5.5, 6.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol</td><td align="center" rowspan="1" colspan="1">5.5 (4.7&#x02013;6.3)</td><td align="center" rowspan="1" colspan="1">4.6 (3.9&#x02013;5.5)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;1.1, &#x02212;0.2)*</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol</td><td align="center" rowspan="1" colspan="1">1.1 (0.9&#x02013;1.4)</td><td align="center" rowspan="1" colspan="1">1.1 (0.9&#x02013;1.3)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.1, +0.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol</td><td align="center" rowspan="1" colspan="1">3.3 (2.6&#x02013;3.8)</td><td align="center" rowspan="1" colspan="1">2.8 (2.1&#x02013;3.3)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.7, &#x02212;0.1)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides</td><td align="center" rowspan="1" colspan="1">1.7 (1.2&#x02013;2.4)</td><td align="center" rowspan="1" colspan="1">1.4 (1.0&#x02013;1.9)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.9, &#x02212;0.1)*</td></tr></tbody></table></table-wrap><table-wrap id="tab5b" orientation="portrait" position="anchor"><caption><p>(b) ETRA-SWITCH trial: changes in lipids from baseline, to Week 24 (mmol/L)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Mean lipid levels (95% C.I)</th><th align="center" colspan="2" rowspan="1">Etravirine group</th><th align="center" colspan="2" rowspan="1">PI control group</th></tr><tr><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Week 24</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Week 24</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cholesterol</td><td align="center" rowspan="1" colspan="1">5.33 (4.48&#x02013;6.31)</td><td align="center" rowspan="1" colspan="1">4.81 (4.14&#x02013;5.64)*</td><td align="center" rowspan="1" colspan="1">4.82 (4.30&#x02013;5.70)</td><td align="center" rowspan="1" colspan="1">5.39 (4.51&#x02013;6.01)</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol</td><td align="center" rowspan="1" colspan="1">1.35 (1.01&#x02013;1.66)</td><td align="center" rowspan="1" colspan="1">1.24 (0.88&#x02013;1.61)*</td><td align="center" rowspan="1" colspan="1">1.30 (1.04&#x02013;1.58)</td><td align="center" rowspan="1" colspan="1">1.24 (1.01&#x02013;1.37)</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol</td><td align="center" rowspan="1" colspan="1">2.85 (2.41&#x02013;3.83)</td><td align="center" rowspan="1" colspan="1">3.13 (2.36&#x02013;3.52)</td><td align="center" rowspan="1" colspan="1">2.98 (2.43&#x02013;3.52)</td><td align="center" rowspan="1" colspan="1">2.77 (2.20&#x02013;3.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides</td><td align="center" rowspan="1" colspan="1">1.89 (1.20&#x02013;2.60)</td><td align="center" rowspan="1" colspan="1">1.21 (0.90&#x02013;1.50)*</td><td align="center" rowspan="1" colspan="1">1.20 (0.80&#x02013;2.01)</td><td align="center" rowspan="1" colspan="1">1.40 (0.85&#x02013;2.73)</td></tr></tbody></table><table-wrap-foot><fn><p>*<italic>P</italic> &#x0003c; 0.05, comparison between treatments; IQ range: interquartile range; ETR: etravirine; EFV: efavirenz.</p></fn></table-wrap-foot></table-wrap></table-wrap-group></floats-group></article>